top of page
.jpg)
Maximizing response to cancer immunotherapy in patients with cancer pain
Glycyx has identified a critical issue overlooked in oncology: the negative impact of opioids on the effectiveness of immunotherapy in cancer.
At Glycyx, we aim to significantly improve survival rates and quality of life for cancer patients worldwide by developing innovative therapies that negate the detrimental effects of opioids on cancer immunotherapy.
What we do
As a biotechnology firm ready for Phase 2, Glycyx is pioneering a novel therapeutic solution that reverses the negative effects of opioids and is designed to further enhance the lives of cancer patients by ensuring that essential pain management does not compromise the effectiveness of anti-PD1/PD-L1 cancer treatments. Our mission is to significantly improve survival rates and quality of life for cancer patients worldwide.
bottom of page